ReNewVax’s stated aim is to prevent life-threatening bacterial infections and combat antimicrobial resistance with vaccines. ReNewVax is a next generation vaccine company developing therapeutic vaccines targeting some of the world’s most acute bacterial disease challenges.

Spun out of the University of Liverpool (UoL) to commercialise the intellectual property generatedfrom the work of Dr Marie Yang and Professor Aras Kadioglu, exploiting a reverse vaccinology strategy, ReNewVax is deploying genomic-led, rational discovery approaches to produce a pipeline of programs that offer protection beyond existing traditional vaccines, which opens up access and delivers a step-change in global health security.